Breaking News

MethylGene Reacquires Rights from Celgene

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Celgene has terminated its licensing agreement with MethylGene for oncology histone deacetylase (HDAC) inhibitors, including MGCD0103. As a result, MethylGene will reacquire the rights to these programs. MethylGene also announced plans to implement a strategic initiative to focus its resources on the clinical development of its pipeline.     As part of the termination, Celgene will continue to support MGCD0103 for 90 days to help with the transition. Celgene acquired the rights to MGCD0103 th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters